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Abstract 
The human rcdox protein thioredoxin is an autocrine growth factor for some cancer cells. Redox activity is essential for this function but other 
required structural features of thioredoxin are not known. Two I-mer peptides (I and II) and one 1Cmer pcptide (III) were designed based on the 
amino acid sequence of the redox active site of thioredoxin. Peptide I and peptide III contained the wild-type sequence of thioredoxin while peptide 
II contained serine residues in place of the catalytically active cysteines. Circular dichroism spectroscopy indicated that all three peptides were 
comprised mainly of random coil, with peptide III containing slightly more ordered secondary structure. Peptides I and III were substrates for 
thioredoxin rcductase with KM values of 890 and 265 ,uM, respectively. The redox inactive peptide II could not compete with thioredoxin for reduction 
by thioredoxin reductase in a coupled insulin reduction assay. However, peptide II was a competitive inhibitor for the reduction of $5’~dithiobis- 
(2nitrobenzoic acid) by thioredoxin reductase. All three peptides gave only background levels of stimulation of the proliferation of Swiss 3T3 murine 
fibroblasts when compared to the stimulation caused by thioredoxin. These results suggest hat while the ability of thioredoxin to stimulate cellular 
proliferation is redox-dependent, more information than that contained in the redox active site domain alone defined by 14 amino acids is required. 
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1. Iutroduction 
Regulation of the intracellular redox state is critical 
for cell viability. Thioredoxin (Trx) and the flavoenzyme 
TR (EC 1.6.4.5) comprise a redox system found in nearly 
all cells and the active site amino acid sequence of Trx 
is highly conserved between bacterial and mammalian 
cells [ 11. Two half-reactions occur in the reduction of Trx 
by TR, in which the reduction of the FAD prosthetic 
group of TR by NADPH and electron transfer to the 
active site cysteines in TR occurs f&t. The second half- 
reaction is the reduction of bound oxidized Trx [2]. Trx 
functions in vitro as a co-factor for reduction of proteins 
[3,4], as a protective system against oxidizing species 
[5,6], and can catalyze the in vitro folding of proteins [7j. 
Trx has also been shown to modulate the activity of 
transcription factors such as AP-1 [8,9], TFIIIC [lo], 
BZLFl [ 111, and NF-KB [ 121 and steroid receptors 
[13,14], suggesting a role for Trx in the redox-regulation 
of gene expression. 
*Corresponding author. 
Abbreviations: ADF, adult T-cell derived leukemic factor; CD, circular 
dichroism; DMEM, Dulbecco’s modified Eagles medium; DTNB, 
5,5’-dithiobis-(2-nitrobenzoic a id); DTT, dithiothreitol; FAD, flavin 
adenine dinucleotide; FBS, fetal bovine serum; GSH, glutathione 
(reduced); hFSH, human follicle stimulating hormone; Trx, thiore- 
doxin; TR, thioredoxin reductase. 
Trx is also a growth factor and is identical to the 
previously described leukemic cell autocrine growth fac- 
tor, ADF [15-171. Some human solid cancers have high 
levels of Trx mRNA compared to normal tissue [17] and 
cell lines overexpressing Trx have been shown to secrete 
Trx through a non-classical leaderless ecretory pathway 
[18]. This suggests that Trx may be an autocrine growth 
factor for solid tumors as well as hematopoietic tumors. 
We have found that recombinant human Trx has mito- 
genie activity for fibroblasts which is dependent on a 
redox active form of the protein [ 191. However, the struc- 
tural requirements outside of the cysteines in the cata- 
lytic domain of Trx for reduction by TR and the 
Trx-mediated stimulation of cellular proliferation are 
unknown. 
Two peptides were synthesized which were exact du- 
plicates of the 8 and 14 residues containing the active site 
of Trx, and another 8 residue peptide containing substi- 
tutions of the active site cysteines with serines. We report 
the ability of these peptides to interact with TR, and their 
mitogenic properties. 
2. Materials and methods 
2.1. Peptide synthesis 
Peptides I and III were synthesized off the active site of Trx (Table 
1) and represent amino acids 3&37 and 2740 of human Trx, respec- 
tively [17]. The thiid peptide, peptide II, was similar to peptide I with 
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the exception that it contained serine residues ubstituted for the cyste- 
ine residues, rendering it redox inactive. Peptides were synthesized at 
a 25 pmol scale using a double coupling protocol on a Gilson 422 
automated multiple peptide synthesizer and purified by HPLC to 
areater than 98% nuritv bv Dr. Ron Jasenskv (The Universitv of Ari- 
zona Biotechnology Resource Facilities). Peptides were puriged using 
a gradient Rainin HPLX system with a C-18 RP 21.4 mm x 25 cm 
Dynamax column packed with 5 fl diameter 300 A pore size silica. 
Analytical HPLC entailed a similar HPLC system with a 4.6 mm col- 
umn, a flow-rate of 1 ml/mm, and mobile phase gradients between 0.1% 
TFA in water and 0.1% TFA in acetonitrile. Amino acid analysis was 
performed using an ABI A420 with automated hydrolysis. Capillary 
zone electrophoresis was performed on a Beckman P/ACE 2100. Mo- 
lecular ions were detected using cesium ion induced liquid SIMS per- 
formed on a AMD Intectra double focusing magnetic sector mass 
spectrometer. 
2.2. Thioredoxin reductase assay 
Recombinant human Trx and human placental TR were prepared as 
previously described [17,20]. Two assays were performed to monitor 
TR activity. The 6rst assay monitored the change in absorbance at 
412 mn due to the NADPH-dependent reduction of DTNB by TR [2]. 
The second assay monitored the oxidation of NADPH by the change 
in absorbance at-340 nm in the presence of Trx and insul&[2]. Peptides 
I and III were reduced with an excess of immobilized DTT (Reductacryl 
Reagent, Calbiochem, La Jolla, CA) for a minimum of 10 min at room 
temperature prior to addition into the spectroscopic assays. GSH 
at 2 mM had no activity in the insulin reduction assay. 
2.3. Cell growth conditions 
Swiss murine 3T3 fibroblast cells (2 x 10’) were grown to approxi- 
matelv 70% confluence in DMEM containina 10% FBS. The cells were 
then incubated in DMEM containing 0.5% FBS for 24 h to arrest cell 
growth. To each culture was added either D’IT, GSH, Trx, or the 
peptides as indicated and allowed to incubate for 48 h. Trx and peptide 
samples were reduced with a 3-fold excess of DTT or with immobilized 
DTT prior to addition to the cultures. Cellular proliferation was meas- 
ured by the increase in cell number elative to control cultures with time 
using a hemacytometer following detachment of the cells with 0.025% 
trypsin. 
2.4. CD spectroscopy 
A stoppered l-cm pathlength quartz cuvette was used in an Aviv 
Model &DS spectropolarimeter and 2 PM peptide samples reduced 
with 6 uM DTT were scanned in 5 mM notassium nhosnhate (DH 7.0). 
A total of four scans were signal-averaged from &ich-a buff& blank 
was subtracted to generate the 8nal CD spectra. The estimated percent- 
ages of secondary structure were calculated from the CD spectra with 
the program PROSEC (PROtein SECondary structure estimator ~2.1, 
Aviv Associates, Lakewood, NJ) [21]. 
3. Results 
CD spectra of all three peptides reduced with DTT 
were recorded (Fig. 1). The calculated secondary struc- 
ture of peptide I was random coil (7 1.1%) and turn con- 
tent (25.4%) with a minor proportion of a-helix (3.5%). 
Peptide II was comprised of random coil (81.3%), turn 
content (18.7%) and negligible a-helical content while 
peptide III was comprised of random coil (70.2%), turn 
content (21.5%) and a-helix (8.3%). 
The KM values for reduction of the peptides and Trx 
by human TR in the Trx-specific insulin reduction assay 
are shown in Table 2. The KM value of peptide III was 
265 ,uM, two orders of magnitude higher than the KM 
value for human Trx, and one order of magnitude higher 
than the & for E. coli Trx. A relatively high Krvr value 
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Fig. 1. Circular dichroism spectra of the three peptides. CD scans of 
peptide I (open circles), peptide II (closed circles), and peptide III (open 
squares) at 2 PM concentrations in 5 mM potassium phosphate buffer 
and 6 PM DTT were recorded as described in section 2. The ellipticity 
is given as the molar ellipticity per residue. 
of 890 PM was determined for peptide I. The redox 
inactive peptide II at 2 mM was not a substrate for TR 
in the insulin reduction assay and was unable to compete 
with 45 PM Trx for the reduction of insulin, but was a 
competitive inhibitor for reduction of DTNB by human 
TR with a Ki of 3.8 mM. 
Cell growth studies showed that peptides I and II at 
concentrations of 100 PM stimulated the proliferation of 
Swiss 3T3 murine fibroblasts to 112 and 116% (P > 0.05 
in both cases) of the levels obtained with control cultures, 
respectively, compared to 151% (P < 0.05) by Trx at 
0.5 ,uM (Fig. 2). When the concentrations of peptides I
and II were increased to 1000 ,uM the level of growth 
stimulation did not increase above those attained with 
100 ,uM (data not shown). Peptide III at 10 ,uM stimu- 
lated proliferation to 129% of control levels (P < 0.05) 
and at 100,~M the level was decreased to 105% of control 
levels (Fig. 2). Peptide III at 1 PM concentrations did not 
stimulate cellular proliferation (data not shown). GSH 
at 100 ,uM stimulated cellular proliferation to 119% of 
control levels (P > 0.05) (Fig. 2). Neither 3 nor 100 PM 
DTT change the final cell number relative to control 
cultures with only 0.5% FBS (data not shown). 
Table 1 
Amino acid sequence of human thioredoxin active site synthetic pep- 
tides 
Peptide I Thr-Trp-Cz-Gly-Pro-C&Lys-Met 
Peptide II Thr-Trp-Ser-Gly-Pro-Ser-Lys-Met 
Peptide III Phe-Ser-Ala-Thr-Trp-CC-Gly-Pro-C~-Ly~Met-Ile-Asn- 
pro 
The two active-site cysteines in thioredoxin are underlined. 
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4. Discussion 
Trx has an identical predicted amino acid sequence to 
the leukemic cell autocrine growth factor ADF [17]. We 
have shown that recombinant human Trx is capable of 
stimulating both DNA synthesis and cellular prolifera- 
tion of murine fibroblasts [19]. Furthermore, site- 
directed mutagenesis of the active-site cysteines to serine 
residues resulted in loss of the mitogenic properties. The 
present study was designed to elucidate which other fea- 
tures of Trx were important for enzymatic reduction and 
mitogenesis. 
The CD spectra indicated that the three peptides were 
very similar in structure. They contained a high propen- 
sity for random coil structure, as evidenced by character- 
istic negative ellipticities below 200 nm [22], and minor 
turn content, which is the simplest element of most pep- 
tides in solution [26]. While the active site of intact 
human Trx is B-sheet and random coil [25], peptides in 
solution are comprised of numerous interconverting con- 
formations and, more often than not, do not assume any 
particular structural preference [26]. 
Peptides I and III used in this study were catalytically 
active in a Trx-specific reduction assay with human TR, 
albeit with a 62-fold higher KM value for peptide III and 
a 207-fold higher value for peptide I. Bacterial Trx, 
which has 26% identity in primary structure with human 
Trx, was still a better substrate for reduction by human 
TR than peptide III. The KM value of peptide I in the 
insulin reduction assay was decreased 3-fold by the addi- 
tion of 6 amino acid residues (3 at each end) to the 
sequence of peptide I to produce peptide III. The redox 
inactive peptide II was neither a substrate nor a compet- 
itive inhibitor for TR in the insulin reduction assay, sug- 
gesting that any interaction of peptide II with TR could 
easily be overcome by Trx. However, peptide II could 
compete with DTNB for reduction by TR with a Ki of 
3.8 mM, compared to the previously reported KM value 
for DTNB of 365 ,uM for reduction by TR [20]. This 
suggests that the redox-inactive peptide II is recognized, 
if only very weakly, by TR. 
We found that the ability of the two Trx active-site 
peptides to stimulate cellular proliferation was severely 
decreased compared to Trx, despite the presence of ac- 
Table 2 
KM values of human placental thioredoxin reductase 
Substrate KM value QM) 
Peptide I 890.0 2.44 
Peptide II N.D. N.D. 
Peptide III 265.0 10.08 
Human thioredoxir$ 4.3 3.10 
E. coli thioredoxinb 20.0 3.99 
DTNBb 365.0 1.53 
“nmol NADPH oxidized/minute [2]. N.D.-not determined. 
bAs previously reported [20]. 
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Fig. 2. Cellular proliferation of Swiss 3T3 murine fibroblasts with the 
peptides. Trx (0.5pM), GSH (lOOpM), peptide I and II (lOO@l) and 
peptide III (10 and 100,&I) were added to cell culture dishes containing 
2 x lo5 fibroblast cells in DMEM with 0.5% FBS. After 48 h, the total 
cell number was determined as described in section 2 and data presented 
as a percentage of control cultures containing 3 PM DTT. The asterisk 
(*) denotes that the stimulation by peptide III at 1OpM was statistically 
significant above the control levels with 3 PM D’lT alone (P c 0.05). 
tive-site cysteines. The small stimulation observed with 
100 PM of peptides I were most likely non-specific since 
100pM GSH was able to stimulate to the same low level. 
While the level of cellular proliferation attained with 
10pM peptide III was statistically significant, at 100pM 
concentrations the levels dropped to control levels. 
The results of our study suggest hat the informational 
content in 8 and 14 amino acids of the Trx active site 
alone is insufficient for eliciting the full mitogenic effect. 
It has been reported that the B-subunit of hFSH contains 
a Trx-like active site in the receptor-binding domain [23]. 
In subsequent work, peptides of this domain were shown 
to bind to FSH receptors and propagate the signalling 
effect characteristic of FSH. Substitution of the active 
site cysteines with serines did not block the ability of the 
peptides to bind to the receptors but did abolish the 
transduction of the signal across the membranes [24]. 
Thus, there is precedent for Trx-like structural motifs 
present in growth factors. However, it is difficult to com- 
pare the results with hFSH and the present study directly 
since the peptides of the Trx-like domain in FSH were 
20 amino acids long, and their enzymatic activity in an 
insulin reduction assay were not determined. However, 
the work does suggest hat the Trx-like domains within 
the 20 amino acids may contain sufficient structural in- 
formation for propagating signal(s) across the cell mem- 
brane. Even though peptide III could be reduced by TR, 
the 14 amino acid peptides panning the active site of Trx 
are not sufficient to stimulate cellular proliferation. 
These results suggest hat in addition to redox-activity 
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the presence of other structural domains in Trx than that 
contained in the 14 amino acids may be necessary for 
eliciting the same extent of growth signal as that induced 
by wild-type Trx. 
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